Latest news
SystImmune doses first patient in Phase III trial for ES-SCLC - Clinical Trials ArenaClinical Trials Arena · Thu, 06 Aug 2026 10:25:17 GMTSystImmune Announces First Patient Dosed in Global Phase 3 Trial of BL-M14D1 in First-Line Extensive-Stage Small Cell Lung Cancer - PR NewswirePR Newswire · Wed, 05 Aug 2026 12:00:00 GMTSummit Therapeutics Further Expands Ivonescimab Global Development Program with Phase II/III HARMONi-GU1 Study in 1L Bladder Cancer - Business WireBusiness Wire · Wed, 05 Aug 2026 11:00:00 GMTAscletis receives FDA clearance to begin Phase III ASC30 programme - Clinical Trials ArenaClinical Trials Arena · Tue, 04 Aug 2026 10:29:25 GMTIs Global Phase 3 ZENITH AD Rezpegaldesleukin Program Altering The Investment Case For Nektar Therapeutics (NKTR)? - simplywall.stsimplywall.st · Mon, 03 Aug 2026 22:18:15 GMTAscletis Announces Initiation of Global Phase III for Oral Small Molecule GLP-1, ASC30 and Positive Preclinical Data for Its First-in-Class Oral Small Molecule GLP-1/GIP/Amylin Fixed-Dose Combination - Yahoo FinanceYahoo Finance · Mon, 03 Aug 2026 10:55:00 GMTKaryopharm Announces Topline Results from Phase 3 XPORT-EC-042 Trial in Endometrial Cancer - KaryopharmKaryopharm · Thu, 30 Jul 2026 07:00:00 GMTGSK plc (NYSE: GSK) sees Ris-Rez hit phase III goal in relapsed osteosarcoma - Stock TitanStock Titan · Tue, 28 Jul 2026 17:04:21 GMT